These are the top Wall Street analyst upgrades, downgrades and initiations seen on Tuesday, June 3, 2014. They include Apple, Allergan, Broadcom, China Mobile, Devon Energy and Kroger.
ThinkstockCanada-based Valeant Pharmaceuticals Inc. (NYSE: VRX) has raised its offer for Allergan Inc. (NYSE: AGN) for the second time this week. The latest offer, announced just minutes ago includes $72 a share…
These are the top Wall Street analyst upgrades, downgrades and initiations seen on Tuesday, May 13, 2014. They include Allergan, Rackspace, Baker Hughes and Time Warner.
Allergan has been a great company, and it can still be one in the future. The question is whether this greatness will be as an independent company or as a subsidiary of…
These are the top analyst upgrades, downgrades, and initiations seen from Wall Street research firms on Monday. April 28, 2014. They include AIG, CenturyLink, Deckers Outdoor and Whole Foods.
These are the top Wall Street analyst upgrades, downgrades and initiations seen on Wednesday, April 23, 2014. They include Allergan, Galmed Pharmaceuticals, GM, Sirius XM and SunPower.
Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to outperform for the balance of 2014. Here are some of the top…
The equity strategists at Credit Suisse have used the sell-off to make some massive changes in their Top Picks list. Stocks are added in six sectors allowing a wide range of top…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, February 4, 2014. They include Chevron, Gap, Merck, Microsoft and Zynga.
Analysts at at Merrill Lynch see 2014 as a promising year for biotech mergers and acquisitions. A new research report shows which companies they believe will make acquisitions or which will be…
ThinkstockMany fundamental analysts will tell you the chart followers are nothing more than people reporting after-the-fact data. The reality on Wall Street is that a great chart pattern combined with solid fundamentals…
ThinkstockThe drug and pharmaceutical sector is supposed to be a defensive one by nature, even if this week’s government shutdown and impending debt ceiling weighed heavily on biotech stocks. Credit Suisse’s Vamil…
ThinkstockTypically, specialty pharmaceutical companies either provide generic versions of former top-selling branded drugs or they may focus on drugs that target rare or hard to treat diseases as orphan drug manufacturers. One…
When we screen stocks at the Wall Street firms we cover, we always are anxious to provide our readers with the stocks that the top firms feel have the most upside from…
ThinkstockPharmaceutical giant Allergan Inc. (NYSE: AGN) saw its stock climb to an all-time high of more than $116 a share in April before slipping, sliding, stumbling and crashing to below $85 last…
Paul Ausick 
